Post-resuscitation shock: recent advances in pathophysiology and treatment

Mathieu Jozwiak1,2*, Wulfran Bougouin3,4,5,10, Guillaume Geri6,7,8,10, David Grimaldi9,10 and Alain Cariou1,2,4,5,10

Abstract

A post-resuscitation shock occurs in 50–70% of patients who had a cardiac arrest. It is an early and transient complication of the post-resuscitation phase, which frequently leads to multiple-organ failure and high mortality. The pathophysiology of post-resuscitation shock is complex and results from the whole-body ischemia–reperfusion process provoked by the sequence of circulatory arrest, resuscitation manoeuvres and return of spontaneous circulation, combining a myocardial dysfunction and sepsis features, such as vasoplegia, hypovolemia and endothelial dysfunction. Similarly to septic shock, the hemodynamic management of post-resuscitation shock is based on an early and aggressive hemodynamic management, including fluid administration, vasopressors and/or inotropes. Norepinephrine should be considered as the first-line vasopressor in order to avoid arrhythmogenic effects of other catecholamines and dobutamine is the most established inotrope in this situation. Importantly, the optimal mean arterial pressure target during the post-resuscitation shock still remains unknown and may probably vary according to patients. Mechanical circulatory support by extracorporeal membrane oxygenation can be necessary in the most severe patients, when the neurological prognosis is assumed to be favourable. Other symptomatic treatments include protective lung ventilation with a target of normoxia and normocapnia and targeted temperature management by avoiding the lowest temperature targets. Early coronary angiogram and coronary reperfusion must be considered in ST-elevation myocardial infarction (STEMI) patients with preserved neurological prognosis although the timing of coronary angiogram in non-STEMI patients is still a matter of debate. Further clinical research is needed in order to explore new therapeutic opportunities regarding inflammatory, hormonal and vascular dysfunction.

Keywords: Cardiac arrest, Coronary angiogram, Ischemia–reperfusion syndrome, Mean arterial pressure, Myocardial dysfunction, Targeted temperature management, Vasopressors

The concept of post-resuscitation shock

Outcome of cardiac arrest (CA) remains very poor. Over 60% of patients with out-of-hospital cardiac arrest (OHCA) will die without sustainable return of spontaneous circulation (ROSC) [1]. Among patients with sustainable ROSC, intensive care unit (ICU) mortality remains high, ranging from 60% [2, 3] to 80% [1, 4] of patients. In-hospital mortality after OHCA mainly results from different causes including recurrent CA, irreversible anoxic brain damage (including brain death), as well as comorbid withdrawal of care [5, 6]. In addition, a substantial proportion of these post-CA patients will suffer from a severe hemodynamic impairment that may worsen organ damages and may lead to death in the first hours or days. All these complications are closely related to the duration of no-flow and low-flow of CA and thus to the severity of the oxygen debt of the different organs.

The first description of this post-resuscitation shock was provided by Vladimir Negovsky more than 45 years ago [7]. In a series of animal experiments and clinical observations, he has reported a myriad of clinical and biological changes that could be observed as a consequence of the whole-body ischemia and reperfusion provoked by CA. Among these disorders, the hemodynamic
impairment is one of the most frequent and most severe alterations. Today, it is commonly accepted that after resuscitation and ROSC, the combination of tissue hypoperfusion and arterial hypotension requiring a continuous infusion of vasopressor may correspond to the most pragmatic definition of this shock [3, 8, 9]. Using this definition, the incidence of the post-resuscitation shock ranges between 50 and 70% [3, 8, 9]. In a retrospective cohort of patients admitted in ICU after an OHCA, Lemiale et al. reported a global incidence of 68%, and they also identified some factors (male gender, shockable rhythm, time to ROSC) associated with its occurrence [3].

In-hospital mortality attributable to this post-resuscitation shock varies between 20 and 55% [2, 3, 5] and most often results from multiple-organ failure, including (1) myocardial dysfunction in up to two thirds of patients [10], (2) acute renal failure in 10–80% of patients according to the definition used with a pooled incidence of 37% [11], requiring renal replacement therapy in one third of patients [12] and associated with long-term occurrence of chronic kidney disease [13], (3) hypoxic hepatitis in almost 15% of patients [14, 15] and (4) metabolic acidosis in up to 90% of patients [16]. All these organ failures were shown to be associated with poor outcome in this setting. In this review, we aimed at focusing on the recent advances in pathophysiology and treatment of post-resuscitation shock.

Pathophysiology of post-resuscitation shock
The pathophysiology of post-resuscitation shock is both due to the cause of CA and to the ischemia–reperfusion syndrome, which results in a complex and multifactorial puzzle of organ dysfunctions. Whatever the aetiology of CA, the post-resuscitation shock is mainly a combination of myocardial dysfunction, vasoplegia and hypovolemia.

Myocardial dysfunction
In a pivotal study combining angiographic data and pulmonary artery catheter monitoring, Laurent and colleagues prospectively described the hemodynamic profile of consecutive patients after CA from cardiac origin before ICU admission at the time of initial left ventricular angiography and within the first 72 h of ICU stay [17]. When left ventricular angiography was performed, the ejection fraction was reduced in all patients, whereas filling pressure was increased in patients with hemodynamic instability but low to normal in patients without hemodynamic instability. Few hours after ICU admission, the cardiac index was found to be decreased with low or normal filling pressure in all patients, suggesting hypovolemia. Thereafter, the cardiac index gradually improved with a return to normal values within 24 h, whereas filling pressure remained unchanged over time. Despite improvement of cardiac index, all patients required large amount of fluid administration and high doses of vasopressors within the first 72 h to maintain acceptable mean arterial pressure (MAP) level [17]. On the whole, these observations were suggestive of an early and severe myocardial dysfunction, usually regressive within 48 h, associated with a vasoplegia.

Using echocardiography, it has been shown that this post-resuscitation myocardial dysfunction is very common, concerning up to 70% of the patients [10, 18]. The most common pattern is an early and transient systolic and diastolic left ventricular dysfunction [17], which can be considered as a model of myocardial stunning following the ischemia–reperfusion syndrome [19]. Of course, this myocardial dysfunction is very common when CA results from a coronary occlusion. However, this myocardial dysfunction may be worsened by repeated defibrillations (especially when using a monophasic and high-energy current), and may also be partly considered as an “adrenergic cardiopathy”, as illustrated by the independent association between the epinephrine dose administered during cardiopulmonary resuscitation and the severity of the cardiac dysfunction [20].

Vasoplegia
Regarding the vasoplegia that is commonly observed as a consequence of the ischemia–reperfusion syndrome, two mechanisms are mainly suspected on the basis on prospective human studies. First, neutrophils accumulation, neutrophil-endothelial interaction and neutrophils activation in microvessels following global ischemia and reperfusion lead to endothelial cell dysfunction [21]. The latter increases the transduction of inducible NO-synthase, which in turn induces a relaxation of vascular smooth muscle cells and promotes the activation of the coagulation cascade [22]. Second, the reactive oxygen species generated by the ischemia–reperfusion syndrome activate the innate immune cells. It leads to an increase in inflammatory cytokines release and inducible NO-synthase expression, both worsening the endothelial dysfunction and thus vasoplegia [23, 24]. Since these two mechanisms are very similar to those involved in the pathophysiology of sepsis, the post-resuscitation shock is frequently considered as “a sepsis-like syndrome”. In addition, an authentic sepsis may also contribute to this hemodynamic profile as infectious complications are very common at this stage [25].

Hypovolemia
Hypovolemia after CA is common but often undertreated, because of the fear of fluid overload in these patients with potential myocardial dysfunction. It results
from vasoplegia (relative hypovolemia due to the mismatch between contents and container), from the capillary-leak syndrome in the most severe patients with prolonged resuscitation before ROSC and/or under extracorporeal life support (ECLS) [26] and in a later phase, from the third compartment syndrome related to ileus and intestinal injury.

**Splanchnic dysfunction and endotoxemia**

Some human and prospective studies have suggested that gut injury could also contribute to the vasoplegia observed in the post-resuscitation shock through its ability to provoke or worsen a systemic inflammatory response [27–29]. Indeed, in post-CA patients, markers of intestinal injury are increased and endotoxemia is frequent [27, 28], this latter being associated with the severity of vasoplegia [29]. However, its incidence is still unknown and the relationship between post-resuscitation shock and gut injury is complex, as the two are closely intertwined.

**Hormonal dysfunction**

A relative adrenal insufficiency could also participate to the vasoplegia observed during the post-resuscitation shock. Pène and colleagues prospectively performed corticotropin-stimulation test in consecutive post-CA patients admitted in ICU and they observed that 52% of these patients had a relative adrenal insufficiency that was associated with shock-related mortality [30]. These findings were confirmed by other teams [31, 32], highlighting the concept of both relative adrenal insufficiency and adrenal reserve exhaustion (as observed in patients with septic shock). In addition, the hypothalamic release of arginine-vasopressin seems to be impaired in patients after CA [33], also contributing to vasoplegia.

Importantly, there is an interindividual variability in the respective weight of the different mechanisms described above in the pathophysiology of post-resuscitation shock. Nevertheless, all are closely interplayed and result in a vicious circle that self-perpetuates it (Fig. 1).

**Management of post-resuscitation shock**

**Symptomatic treatments**

**Early-goal directed therapy**

Similarities between septic and post-resuscitation shock led some authors to advocate for post-resuscitation shock an early-goal directed therapy strategy including hemodynamic resuscitation and therapeutic hypothermia [34, 35]. The hemodynamic resuscitation that is proposed is based on an aggressive step-by-step strategy including fluids, vasopressors, inotropes and blood transfusion, in order to target predefined MAP level and to normalize the central venous oxygen saturation, used as a surrogate of oxygen delivery within the first hours of therapy. Preliminary results from an exploratory study including 20 patients without systematic assessment of cardiac function suggested that this early-goal directed therapy did not improve mortality after comparison with matched historic controls [34]. A recent multicentre and randomized study confirmed that such an early-goal directed...
therapy strategy was neither shown to improve mortality nor to limit the extent of anoxic brain damage or neurological outcome despite an improvement in cerebral oxygenation [35]. Nevertheless, it might be reasonable to use such a strategy in post-resuscitation shock in order to maintain an adequate organ perfusion (Fig. 2).

**Vasopressors and inotropic drugs**

Besides fluid administration, the hemodynamic management of post-resuscitation shock is mostly based on vasopressors because of the severe vasoplegia and vasodilation, in combination with inotropes when post-resuscitation myocardial dysfunction is present (Fig. 2).

Norepinephrine should be considered as the first-line vasopressor, in order to avoid arrhythmogenic effects of other catecholamines. Regarding inotropes, dobutamine is the most established treatment in this situation [36, 37]. These two animal studies showed that dobutamine successfully overcome the global systolic and diastolic left ventricular dysfunction resulting from prolonged CA [36, 37]. In addition, the most effective dose would be 5 µg/kg/min: a lower dose would be inefficient and a higher dose would increase in a too large extent the myocardial oxygen consumption [37]. Importantly, this threshold value of 5 µg/kg/min could not necessarily be transposed in humans and the potential detrimental effects of higher dose of dobutamine deserve further studies.

Levosimandan could also be an interesting alternative to dobutamine in this setting, as suggested by an animal study [38], as well as phosphodiesterase inhibitor such as milrinone [20]. Nevertheless, nothing was done in this field since nearly one decade and both treatments still require further clinical validation and are not recommended for the management of post-resuscitation shock so far.

**Target for mean arterial pressure level**

Because arterial hypotension is associated with poor neurological outcomes in patients after CA [39] and because the autoregulation of cerebral blood flow may be impaired after ROSC [40], the MAP level is an important therapeutic goal in patients with post-resuscitation shock. In this regard, several observational studies have suggested that maintenance of higher MAP levels was associated with a better brain tissue oxygenation [41], an improvement in survival [42, 43] and a better neurological outcome [44]. In a recent multicenter and randomized study (COMACARE study), it has been shown in 120 comatose patients after OHCA that, targeting a low-normal (65–75 mmHg) or a high-normal (80–100 mmHg) MAP level for the first 36 h after ICU admission neither affect the neuron-specific enolase (NSE) serum level nor mortality or neurological outcomes [45]. However, targeting a high-normal MAP level was recently shown to decrease troponin release as a marker of myocardial injury [46]. Thus, although it is currently recommended that hemodynamic treatments should be guided by arterial pressure, the optimal MAP level still

---

**Fig. 2** Proposal for management of post-resuscitation shock. ECLS extracorporeal life support
remains unknown and may probably vary according to patients [47].

**Ventilatory management**

A vast majority of post-CA patients are mechanically ventilated, according to current guidelines [47]. Regarding protective lung ventilation strategies, it has been shown in a retrospective study that lower tidal volumes (<6 mL/kg) were independently associated with favorable neurocognitive outcome, more ventilator-free days and more shock-free days [48]. Regarding the positive end-expiratory pressure (PEEP) level, a secondary analysis of three international prospective, observational and multicenter studies including 812 patients mechanically ventilated after CA, showed that the PEEP level increased from 3.5 ± 3 to 6.5 ± 3 cmH2O between 1998 and 2010 and that lower PEEP levels were independently associated with the occurrence of ICU-acquired pneumonia [49]. Thus, although no study has specifically investigated this issue, a PEEP level between 4 and 8 cmH2O [47], or higher in patients with acute respiratory distress syndrome [50], seems to be rational. To summarize, it seems to be reasonable to consider protective lung ventilation in such patients who are exposed to a marked inflammatory response.

Hypoxemia and hypercapnia should be strictly controlled, since both may contribute to secondary brain injury, even in patients receiving ECLS [51]. However, the role of oxygenation remains still debated: the results of an exploratory post-hoc substudy of the Target Temperature Management (TTM) trial suggested that hyperoxemia and hypoxemia were not associated with poor neurological outcome and increase in biomarker of brain injury [52], whereas some retrospective and/or meta-analysis of experimental and clinical studies found that hyperoxemia could be linked to poor neurological outcome [53] through oxidative stress and potential direct pulmonary and cardiovascular toxicity of oxygen [54]. Finally, preliminary experimental [55, 56] and human [57, 58] studies might suggest a potential interest of hyperbaric oxygenation as a curative treatment of reperfusion injury, with a decrease in neuronal death [55, 56] and an improvement of neurological outcomes [55–57] or cognitive functions [58] after CA not related to carbon monoxide poisoning or gas embolism.

In the multicenter and randomized COMACARE study, targeting a low-normal or a normal-high range in partial pressure of arterial carbon dioxide (PaCO2) and oxygen (PaO2) during the first 36 h after ICU admission did not affect NSE serum level [59]. However, high-normal PaCO2 (5.8–6.0 kPa) and moderate hyperoxia (PaO2: 20–25 kPa) resulted in better cerebral oxygenation [59]. Another large multicenter and randomized trial comparing normocapnia and mild hypercapnia in patients after OHCA is still ongoing (NCT03114033).

At that time, current guidelines recommend to target normoxia and normocapnia during the first 72 h [47].

**Targeted temperature management**

Targeted temperature management (TTM) is currently recommended in patients after OHCA with initial shockable rhythm who remain comatose after ROSC and is suggested in patients after OHCA with non-shockable rhythm or after in-hospital CA with any initial rhythm who remain comatose after ROSC, for at least 24 h [47, 60, 61]. TTM should be started immediately at ICU admission [62]. However, the optimal target temperature [63, 64], the optimal duration [65] of TTM as well as the cooling procedures [66–68] are still matter of debate.

Beyond neuroprotective effects [69], TTM might also have cardioprotective effects, especially in patients experiencing post-resuscitation myocardial dysfunction [20]. Currently, there is no sufficient data to contraindicate TTM in patients with post-resuscitation shock. However, when TTM is used, there are some arguments that suggest avoiding lowest temperature targets. In a sub-study of the TTM trial, TTM at 33 °C was associated with more frequent hemodynamic alterations (decreased heart rate, elevated levels of lactate, and need for increased vasopressor support) compared with TTM at 36 °C [70].

**Specific treatments**

**Coronary reperfusion**

There is a large consensus for considering acute coronary disease as a frequent cause of CA in adult patients [71, 72]. By analogy with the management of other acute coronary syndromes, the most common strategy is to perform a coronary angiogram (CAG) as soon as possible, since many observational studies reported a significant association between early percutaneous coronary intervention and improved outcome after OHCA [73–75]. Current guidelines argue for a large use of early CAG in these patients [47, 76]. Once the interest of percutaneous coronary intervention in CA of ischemic cause is universally acknowledged, there are several unsolved issues. Among these issues, selection of the best candidates and optimal timing for CAG are the most debated. Regarding the indication, the decision for early CAG should be based on a panel of arguments encompassing previous medical history, warning symptoms before arrest, initial cardiac rhythm, electrocardiographic pattern after ROSC, and biomarkers if available. In addition, recent retrospective data highlight the interest of focusing coronary interventions for patients with preserved neurological status [77]. Regarding the timing, there is a consensus for early CAG (i.e., as soon as possible after
hospital arrival) in ST-elevation myocardial infarction (STEMI) patients with preserved neurological prognosis, since this “scoop and run” strategy offers the benefit of both immediate diagnosis and treatment and may avoid secondary cardio-circulatory deterioration related to untreated coronary occlusion [47]. By contrast, a “wait and see” strategy (delayed CAG) may be proposed in patients without evidence of STEMI [78]. Thus, Lemkes and colleagues showed in a multicenter and randomized controlled trial that the survival of patients who had CA without signs of STEMI was similar regardless the timing of CAG. In addition, a delayed strategy avoided a significant number of useless CAG [78]. These two strategies (early versus delayed CAG in non-STEMI patients) are currently evaluated in several ongoing studies (DISCO NCT02309151, COUPE NCT02641626, TOMAHAWK NCT02750462, PEARL NCT02387398, NCT02587494, EMERGE NCT02876458), which should be helpful for establishing future guidelines.

**Extracorporeal life support**

Mechanical circulatory support can be necessary in the most severe forms of post-resuscitation shock, when the neurological prognosis is assumed to be favourable. Several technics have been proposed, such as Impella [79], or intra-aortic balloon pump [80]. However, the post-resuscitation myocardial dysfunction can be very severe and global [10, 20] with unpredictable severity, up to refractory cardiogenic shock. For these reasons, veno-arterial extra-corporeal membrane oxygenation is the most commonly employed ECLS technic in the post-resuscitation shock [81].

The main issue is to identify the most suitable patients with post-resuscitation shock eligible for ECLS. Bascom and colleagues have proposed to use the “CREST score” (Table 1) for early identification of patients carrying the highest risk of circulatory-related death after CA, who could, therefore, be elective candidates for ECLS [82]. It has also been shown that in patients with post-resuscitation shock treated by ECLS, admission SOFA score < 14, initial shockable rhythm and international normalized ratio < 2.4 as well as initial arterial pH (odds ratio = 1.7 per 0.1 increase) and implantation of ECLS later than 24 h after ROSC were associated with survival and thus could be useful triage tools in such patients [83, 84]. Interestingly, 25–28% of these ECLS patients survived to hospital discharge with favourable neurological and long-term outcome [83, 84], supporting the use of ECLS in carefully selected patients with post-resuscitation shock [85].

Beyond hemodynamic severity, the neurological prognosis should be also considered before the decision of ECLS in patients with post-resuscitation shock. Several scores have been proposed to assess neurological prognosis after OHCA [77, 86–88] (Table 1) and could be useful to guide the therapeutic strategy in patients experiencing CA [77].

To summarize, ECLS should be considered as a bridge-to-recovery only in the most severe patients with post-resuscitation shock with preserved neurological status, assessed by some selected prognostic factors or specific scores (Table 1).

**Epurative treatments**

Regards to the important release of inflammatory mediators and cytokines in patients with post-resuscitation shock, animal studies have suggested that an early blood removal of inflammatory mediators could be associated with an improvement in hemodynamics and outcome [89, 90]. However, inflammatory mediators are relatively large molecules and it is thus unlikely that the membranes used for conventional renal replacement therapies allow one to achieve high level of cytokines removal, conversely to other alternative extracorporeal blood purification therapies. In this regard, Laurent and colleagues prospectively assessed the effects of high-volume hemofiltration, a technique known to allow a better removal of cytokines, in consecutive patients with post-resuscitation shock [91]. Compared to conventional renal replacement therapy, the use of high-volume hemofiltration was associated with a better survival, while there was no significant effect on the cytokines levels [91]. Such a lack of effect on cytokines removal on hemodynamics was confirmed in more recent animal [92] or human studies [93] pleading against cytokine removal in ischemia–reperfusion syndrome, whatever the epurative technique used.

This lack of effect may be explained by several mechanisms: (1) the lower cytokines level at ICU admission (compared to patients with septic shock) [22], (2) the quick decrease in cytokines level after the initial and transient increase at the time of ROSC [91, 92], and/or (3) the membrane fouling, resulting in a progressive better removal of molecules with lower molecular weights despite the use of high cut-offs membranes.

Thus, given the potential prolonged effects on hemodynamics of the inflammatory mediators and cytokines despite their very short half-life, future therapies should rather focus on agents able to block the inflammatory cascade following the release of inflammatory mediators and cytokines, than to epurative treatments.

**Steroids**

The use of steroids in patients with post-resuscitation shock is still debated despite the evidence for the hormonal dysfunction. Although beneficial effects of glucocorticoids administration during cardiopulmonary
resuscitation have been suggested by retrospective or pilot studies [94, 95], only a few studies have focused on the impact of corticosteroids administration in successfully resuscitated patients. In a randomized controlled trial by Mentzelopoulos and colleagues [96] comparing a strategy combining vasopressin, methylprednisolone and epinephrine versus epinephrine alone, patients who were successfully resuscitated received either a stress-dose of hydrocortisone (300 mg daily for 7 days) or saline. Interestingly, the administration of hydrocortisone (at least one dose) improved survival to hospital discharge with favorable neurological status, suggesting a potential benefit of steroids. Nevertheless, because multiple interventions were concomitantly used, it is difficult to affirm the effect of hydrocortisone itself on outcome. More recently, Donnino et al. evaluated the interest of hydrocortisone administration (300 mg daily for 7 days) in a randomized, double-blind, placebo-controlled trial including 50 patients with refractory post-resuscitation shock [97]. Compared to placebo administration, no beneficial effect of hydrocortisone on mortality, time to shock reversal or shock reversal, or neurological outcome was observed. However, patients with documented adrenal insufficiency who received hydrocortisone tended to achieve shock reversal more frequently than those receiving placebo [97].

Table 1 Summarize of the different scores that can be used to select eligible patients with post-resuscitation shock to extracorporeal life support

| Scores                                      | Points |
|---------------------------------------------|--------|
| Assessment of risk of circulatory-related death |        |
| CREST score                                 |        |
| History of coronary artery disease          | 1      |
| Non-shockable rhythm                        | 1      |
| LVEF at time of admission < 30%             | 1      |
| Shock at presentation                       | 1      |
| Ischemic time > 25 min                      | 1      |
| Assessment of neurological prognosis        |        |
| CAHP score                                  |        |
| Age                                         | 1.1 x (age – 10) |
| Setting                                     | 0 if public setting and 24 if home |
| Initial Rhythm                              | 0 if shockable and 27 if non-shockable |
| Collapse-BLS duration (min)                 | 2.8 x duration |
| BLS-ROSC duration (min)                     | 0.8 x duration |
| pH                                          | 585–77 x pH |
| Epinephrine dose during resuscitation (total)| 0 if 0 mg and 27 if 1 or 2 mg |
| OHCA score                                  |        |
| Ventricular fibrillation or tachycardia      | – 13 if the initial recorded rhythm is VF or ventricular tachycardia |
| No-flow interval (min)                       | +6 x ln (no-flow interval) |
| Low-flow interval (min)                      | +9 x ln (low-flow interval) |
| Serum creatinine (µmol/L)                   | - 1434/serum creatinine |
| Lactate (mmol/L)                            | + 10 x ln (arterial lactate) |
| CAST score                                  |        |
| Initial rhythm                              | Shockable 1 Non-shockable 3 |
| Witness/ROSC time (min)                     | < 20 min 2 20 min 3 |
| pH                                          | ≥ 7.31 2 7.16–7.30 3 7.01–7.15 4 ≤ 7.00 5 |
| Lactate (mmol/L)                            | ≤ 5.0 1 5.1–10.0 2 10.1–14.0 3 ≥ 14.1 4 |
| Motor component of Glasgow coma scale        | ≥ 2 1 ≥ 3 2 ≥ 4 3 |
| Gray matter attenuation to white matter attenuation ratio | ≥ 1.201 1 1.151–1.200 2 1.150 3 ≤ 1.150 4 |
| Albumin (g/dL)                              | ≥ 3.6 1 3.1–3.5 2 ≤ 3.0 3 |
| Hemoglobin (g/dL)                           | ≥ 13.1 1 11.1–13.0 2 ≤ 11.0 3 |

For the CREST score, ischemic time was defined as estimated time from cardiac arrest to return of spontaneous circulation

LVEF left ventricular ejection fraction, BLS basic life support, Ln natural logarithm, ROSC return of spontaneous circulation
In a recent work, Tsai et al. have shown in a retrospective analysis of the Taiwan National Health Insurance Research Database that the administration of steroids during the post-CA period was associated with better survival to hospital discharge and 1-year survival in patients receiving low-dose of steroids (<50 mg daily equivalent prednisone, i.e., about 200 mg/day of hydrocortisone) only [98]. Conversely, higher doses of steroids could even be associated with worse outcomes than in patients not receiving steroids [98]. Despite the retrospective design of the study and the fact that these results come from health insurance databases (with many potential confounders), the administration of low-dose of hydrocortisone in patients with post-resuscitation shock might be of interest, especially in patients with associated relative adrenal insufficiency. Further randomized trials are needed to clarify the potential interest of steroids in patients with post-resuscitation shock.

**New perspectives**

Although the impairment of the hypothalamic release of arginine-vasopressin contributes to the vasoplegia of the post-resuscitation shock [33], only few data are available regarding the potential interest of vasopressin administration in patients with post-resuscitation shock [96, 99] and only one study investigated the potential isolated effect of vasopressin administration in such patients [99]. Thus, Mayr and colleagues retrospectively reported the hemodynamic effects of arginine-vasopressin administration in 23 patients with post-resuscitation shock unresponsive to hemodynamic therapy including fluids, norepinephrine, epinephrine and milrinone. Arginine-vasopressin administration significantly increased MAP and decreased the catecholamines requirement and blood lactate level [99]. Despite the retrospective design of the study and the small number of patients, these results should encourage to further evaluate the effects of arginine-vasopressin, possibly in combination with low-dose of hydrocortisone, in an attempt to achieve the “hormonal healing” in patients with post-resuscitation shock.

Finally, to further investigate the gut dysfunction in post-CA patients, an ongoing study (ENTRACT study, NCT02349074) aims at determining the incidence of upper gastro-intestinal tract ischemia by performing systematic gastroscopy in all patients experiencing CA.

**Conclusion**

The post-resuscitation shock results from the whole-body ischemia–reperfusion process provoked by the sequence of circulatory arrest, resuscitation manoeuvres and return of spontaneous circulation. It is an early and transient complication of the post-resuscitation phase, which frequently results in multiple-organ failure and high mortality. Its pathophysiology is complex and multifactorial, combining a myocardial dysfunction and characteristics common to sepsis, such as vasoplegia, hypovolemia and endothelial dysfunction. Treatment is based on an early and aggressive hemodynamic management, including ECLS in the most severe patients, associated with coronary reperfusion when needed. Further clinical research is needed in order to explore new therapeutic opportunities regarding inflammatory, hormonal and vascular dysfunction.

**Abbreviations**

CA: Cardiac arrest; CAG: Coronary angiogram; ECLS: Extracorporeal life support; ICU: Intensive care unit; MAP: Mean arterial pressure; NSE: Neuron-specific enolase; OHCA: Out-of-hospital cardiac arrest; PaCO2: Arterial carbon dioxide partial pressure; PaO2: Arterial oxygen partial pressure; PEEP: Positive end-expiratory pressure; ROSC: Return of spontaneous circulation; TTM: Targeted temperature management.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

MJ, WB, GG, DG and AC drafted the manuscript. All authors read and approved the final manuscript.

**Funding**

None.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Bougouin W, Lamhaut L, Marijon E, Jost D, Dumas F, Deye N, et al. Characteristics and prognosis of sudden cardiac death in Greater Paris: population-based approach from the Paris Sudden Death Expertise Center (Paris-SDEC). Intensive Care Med. 2014;40(6):846–54.
2. Laver S, Farrow C, Turner D, Nolan J. Mode of death after admission to an intensive care unit following cardiac arrest. Intensive Care Med. 2004;30(11):2126–8.

3. Lemiale V, Dumas F, Mongardon N, Giovanetti O, Charpentier J, Chiche JD, et al. Intensive care unit mortality after cardiac arrest: the relative contribution of shock and brain injury in a large cohort. Intensive Care Med. 2013;39(11):1972–80.

4. Kilgannon JH, Roberts BW, Reuhl LR, Chansky ME, Dellinger RP, et al. Early arterial hypoxemia is common in the post-cardiac arrest syndrome and associated with increased in-hospital mortality. Resuscitation. 2005;67(2):121–8.

5. Witten L, Gardner R, Holmberg MJ, Wiberg S, Moskowitz A, Mehta S, et al. Reasons for death in patients successfully resuscitated from out-of-hospital and in-hospital cardiac arrest. Resuscitation. 2019;136:93–9.

6. Cour M, Turc J, Madelaine T, Argauld L. Risk factors for progression toward brain death after out-of-hospital cardiac arrest. Ann Intensive Care. 2019;9(1):45.

7. Negovsky VA. The second step in resuscitation—the treatment of the ‘post-resuscitation disease’. Resuscitation. 1972;1(1):1–7.

8. Duval C, Bouguin W, Geri G, L antimath L, Rosencher J, Pene F, et al. Emergency percutaneous coronary intervention in post-cardiac arrest patients without ST-segment elevation pattern: insights from the PROACT II Registry. JACC Cardiovasc Interv. 2016;9(10):1011–8.

9. Argauld L, DeCubas PJ, Giraud F, Jossan C, Riche B, et al. Effect of cyclosporine in nonshockable out-of-hospital cardiac arrest: the CYRUS randomized clinical trial. JAMA Cardiol. 2016;1(5):577–65.

10. Ruiz-Bailen M, Aguayo de Hoyos E, Ruiz-Navarro S, Diaz-Castellanos MA, Rincón-Andrade A, Ovalle C, et al. Early arterial hypotension is common in the post-cardiac arrest syndrome and associated with increased in-hospital mortality. Resuscitation. 2019;136:93–9.

11. Champigneulle B, Geri G, Bouguin W, Dumas F, Arnaout M, Zafrani L, et al. High level of endotoxemia following out-of-hospital cardiac arrest is associated with severity and duration of postcardiac arrest shock. Crit Care Med. 2015;43(12):2597–604.

12. Pene F, Hyvernat H, Mallet V, Cariou A, Carl P, Spaulding C, et al. Prognostic value of relative adrenal insufficiency after out-of-hospital cardiac arrest. Intensive Care Med. 2005;31(6):627–33.

13. Helekhan G, Baugnon T, Thuong M, Monchi M, Dabbane H, Jaby D, et al. Cortisol levels and adrenal reserve after successful cardiac arrest resuscitation. Shock. 2004;22(2):116–9.

14. Oh SH, Kim HJ, Shin YS, Shin JH, Yang HJ, Kim JK, Hyun SY, et al. Relative adrenal insufficiency after cardiac arrest: impact on postresuscitation disease outcome. Am J Emerg Med. 2006;24(6):684–5.

15. Lindner KH, Haak T, Keller A, Bothner U, Lune KG. Release of endogenous vasopressors during and after cardiopulmonary resuscitation. Heart. 1996;75(2):145–50.

16. Gaiselski DF, Band RA, Abella BS, Neumar RW, Fuchs BD, Kolansky DM, et al. Early goal-directed hemodynamic optimization combined with therapeutic hypothermia in comatose survivors of out-of-hospital cardiac arrest. Resuscitation. 2009;80(4):184–218.

17. Ameloot K, De Deyne C, Ertmans W, Ferdinande B, Dupont M, Palmers PJ, et al. Early goal-directed haemodynamic optimization of cerebral oxygenation in comatose survivors after cardiac arrest: the neuroprotect post-cardiac arrest trial. Eur Heart J. 2019;40(42):1804–14.

18. Kern KB, Hilwig RW, Berg RA, Rhee KH, Sanders AB, Otto CW, et al. Postresuscitation left ventricular systolic and diastolic dysfunction: treatment with dobutamine. Circulation. 1997;95(12):2610–3.

19. Vasquez A, Kern KB, Hilwig RW, Heidenreich J, Berg RA, Evy GA. Optimal dosing of dobutamine for treating post-resuscitation left ventricular dysfunction. Resuscitation. 2004;61(2):199–207.

20. Huang L, Weil MH, Tang W, Sun S, Wang J. Comparison between dobutamine and levosimendan for management of myocardial dysfunction. Crit Care Med. 2005;33(3):487–91.

21. Bhat TD, McDonald B, Selkho MS, Griesdale DE. Association between blood pressure and outcomes in patients after cardiac arrest: a systematic review. Resuscitation. 2015;97:1–6.

22. Sundgreen C, Larsen FS, HerKid TM, Knudsen GM, Boesgaard S, Aldershvile J. Autoregulation of cerebral blood flow in patients resuscitated from cardiac arrest. Stroke. 2001;32(12):3186–32.

23. Sekhon MS, Gooderham P, Monen DK, Brasher PMA, Foster D, Cardim D, et al. The burden of brain hypoxia and optimal mean arterial pressure in patients with hypoxic ischemic brain injury after cardiac arrest. Crit Care Med. 2019;47(7):960–9.

24. Ameloot K, Meex I, Gerbrugg C, Jans F, Boer W, Verhaert D, et al. Hemodynamic targets during therapeutic hypothermia after cardiac arrest: a prospective observational study. Resuscitation. 2015;91:56–62.

25. Russo JJ, James TE, Hibbert B, Yousef A, Osborne C, Wells GA, et al. Impact of mean arterial pressure on clinical outcomes in comatose survivors of out-of-hospital cardiac arrest: insights from the University of Ottawa Heart Institute Regional Cardiac Arrest Registry (CAPITAL-CARE). Resuscitation. 2017;113:27–32.

26. Roberts BW, Kilgannon JH, Hunter BR, Puskas I, McReady JH, et al. Association between elevated mean arterial blood pressure and neurologic outcome after resuscitation from cardiac arrest: results from a multicenter prospective cohort study. Crit Care Med. 2019;47(1):93–100.
45. Jakkula P, Pettia V, Skrifvars MB, Hasbacka J, Loisa P, Tiainen M, et al. Targeting low-normal or high-normal mean arterial pressure after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Med. 2018;44(12):2091–101.

46. Ameloot K, Jakkula P, Hasbacka J, Reinkainen M, Pettia V, Loisa P, et al. Optimum blood pressure in patients with shock after acute myocardial infarction and cardiac arrest. J Am Coll Cardiol. 2020;76(7):812–24.

47. Nolan JP, Soar J, Cariou A, Cronberg T, Moulard VR, Deakin CD, et al. European Resuscitation Council and European Society of Intensive Care Medicine guidelines for post-resuscitation care 2015: section 5 of the European Resuscitation Council guidelines for resuscitation 2015. Resuscitation. 2015;95:202–22.

48. Beitel JR, Ghaffour TB, Jindaasa SP, Mueller A, Frutos-Vivar F, Brunetti I, et al. Management and outcome of mechanically ventilated patients after cardiac arrest. Crit Care. 2015;19:215.

49. Sutherland Y, Penuelas O, Muriel A, Vargas M, Frutos-Vivar F, Brunetti I, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9(1):69.

50. Chang WT, Wang CH, Lai CH, Yu HY, Chou NK, Wang CH, et al. Optimum arterial blood oxygen tension in the early postresuscitation phase of extracorporeal cardiopulmonary resuscitation: a 15-year retrospective observational study. Crit Care Med. 2019;47(11):1549–56.

51. Beitler JR, Ghafouri TB, Jinadasa SP, Mueller A, Hsu L, Anderson RJ, et al. Targeting low-normal or high-normal mean arterial pressure after cardiac arrest treated with targeted temperature management. Crit Care Med. 2018;46(4):e279–85.

52. Llitjos JF, Mira JP, Duranteau J, Chiche JD, Combos A, Dreyfuss D, et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest. Br J Anaesth. 2015;115:211–21.

53. Koch A, Vermeulen-Cranch DM. The use of hyperbaric oxygen following cardiac arrest. Br J Anaesth. 1962;34:738–40.

54. Maekel M, Duszczyszki, Zyszkowski M, Ziembnicka A, Salinska E, Hyperbaric oxygen and hyperbaric air treatment result in comparable neural death reduction and improved behavioral outcome after transient forebrain ischemia in the gerbil. Exp Brain Res. 2013;224(1):1–14.

55. Rosenthal RE, Silbergent R, Hof PR, Haywood Y, Fiskum G. Hyperbaric oxygen reduces neuronal death and improves neurological outcome after canine cardiac arrest. Stroke. 2003;34(5):1311–6.

56. Hadanny A, Golan H, Fishlev G, Bechor Y, Volkov O, Suzin G, et al. Hyperbaric oxygen can induce neuroplasticity and improve cognitive functions in patients suffering from anoxic brain damage. Restor Neurol Neurosci. 2015;33(4):471–86.

57. Dumas F, Cariou A, Manzo-Silberman S, Grimaldi D, Vivien B, Rosencher J, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest: a post hoc study of the target temperature management trial. Crit Care Med. 2015;43(2):318–27.

58. Larsen JM, Ravkilde J. Acute coronary angiography in patients resuscitated from out-of-hospital cardiac arrest—a systematic review and meta-analysis. Resuscitation. 2012;83(12):1427–33.

59. Chen G, Passouant O, Dumas F, Bouquion W, Champigneulle B, Arnaout M, et al. Etiological diagnoses of out-of-hospital cardiac arrest survivors admitted to the intensive care unit: Insights from a French registry. Resuscitation. 2017;117:66–72.

60. Dumas F, White L, Stubbs BA, Cariou A, Rea TD. Long-term prognosis following resuscitation from out of hospital cardiac arrest: role of percutaneous coronary intervention and therapeutic hypothermia. J Am Coll Cardiol. 2012;60(1):21–7.

61. Callaway CW, Donnino MW, Fink EL, Geocadin RG, Golan E, Kern KB, et al. Part B: post-cardiac arrest care: 2015 American Heart association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(3):282–380.

62. Manzo-Silberman S, Fichet J, Mathonnet A, Varenne O, Ricome S, Chaib A, et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of Hospital Cardiac Arrest) registry. Circ Cardiovasc Interv. 2010;3(3):200–7.

63. Dumas F, White L, Stubbs BA, Cariou A, Rea TD. Long-term prognosis following resuscitation from out of hospital cardiac arrest: role of percutaneous coronary intervention and therapeutic hypothermia. J Am Coll Cardiol. 2012;60(1):21–7.

64. Estok M, Nejedly L, Hrubovcek P, Smolikova E, Hrubovckx M, Skalicky J, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest: the PRINCESS (Parisian Region Out of Hospital Cardiac Arrest) registry. Circ Cardiovasc Interv. 2018;11(3):294–305.

65. Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen M, et al. Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J Med. 2019;380(15):1397–407.

66. Manzo-Silberman S, Fichet J, Mathonnet A, Varenne O, Ricome S, Chaib A, et al. Percutaneous left ventricular assistance in post cardiac arrest shock: comparison of intra aortic blood pump and IMPHELLA Recover LP.2S. Resuscitation. 2013;84(5):609–15.

67. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olibrich HG, Hausleiter J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287–96.

68. Dumas F, White L, Stubbs BA, Cariou A, Rea TD. Long-term prognosis following resuscitation from out of hospital cardiac arrest: role of percutaneous coronary intervention and therapeutic hypothermia. J Am Coll Cardiol. 2012;60(1):21–7.

69. Callaway CW, Donnino MW, Fink EL, Geocadin RG, Golan E, Kern KB, et al. Part B: post-cardiac arrest care: 2015 American Heart association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18 Suppl 2):S465–82.

70. Bougouin W, Dumas F, Karam N, Maupain C, Manjon E, Lamhaut L, et al. Should we perform an immediate coronary angiogram in all patients after cardiac arrest? Insights from a large French registry. JACC Cardiovasc Interv. 2018;11(3):249–56.

71. Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen M, et al. Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J Med. 2019;380(15):1397–407.

72. Manzo-Silberman S, Fichet J, Mathonnet A, Varenne O, Ricome S, Chaib A, et al. Percutaneous left ventricular assistance in post cardiac arrest shock: comparison of intra aortic blood pump and IMPHELLA Recover LP.2S. Resuscitation. 2013;84(5):609–15.

73. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olibrich HG, Hausleiter J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287–96.

74. Dumas F, White L, Stubbs BA, Cariou A, Rea TD. Long-term prognosis following resuscitation from out of hospital cardiac arrest: role of percutaneous coronary intervention and therapeutic hypothermia. J Am Coll Cardiol. 2012;60(1):21–7.

75. Callaway CW, Donnino MW, Fink EL, Geocadin RG, Golan E, Kern KB, et al. Part B: post-cardiac arrest care: 2015 American Heart association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18 Suppl 2):S465–82.
for refractory cardiogenic shock post-cardiac arrest. Intensive Care Med. 2016;42(12):1999–2007.

84. Bougouin W, Assaoui N, Combes A, Deye N, Lamhaut L, Jost D, et al. Post-cardiac arrest shock treated with veno-arterial extracorporeal membrane oxygenation: an observational study and propensity-score analysis. Resuscitation. 2017;110:126–32.

85. Yannopoulos D, Bartos JA, Raveendran G, Conterato M, Frascone RJ, Trembley A, et al. Coronary artery disease in patients with out-of-hospital refractory ventricular fibrillation cardiac arrest. J Am Coll Cardiol. 2017;70(9):1109–17.

86. Adrie C, Cariou A, Mourgillier B, Laurent I, Dabbane H, Hantala F, et al. Predicting survival with good neurological recovery at hospital admission after successful resuscitation of out-of-hospital cardiac arrest: the OHCA score. Eur Heart J. 2006;27(23):2840–5.

87. Maupain C, Bougouin W, Lamhaut L, Deye N, Diehl JL, Geri G, et al. The CAHP (Cardiac Arrest Hospital Prognosis) score: a tool for risk stratification after out-of-hospital cardiac arrest. Eur Heart J. 2016;37(42):3222–8.

88. Nishikimi M, Matsuda N, Matsui K, Takahashi K, Ejima T, Liu K, et al. CAST: a new score for early prediction of neurological outcomes after cardiac arrest before therapeutic hypothermia with high accuracy. Intensive Care Med. 2016;42(12):2106–7.

89. Grootendorst AF, van Bommel EF, van Leengoed LA, van Zanten AR, Huipen HJ, Groeneveld AB. Infusion of ultrafiltrate from endotoxemic pigs depresses myocardial performance in normal pigs. J Crit Care. 1993;8(3):161–9.

90. Grootendorst AF, van Bommel EF, van Leengoed LA, Nabuurs M, Bourman CS, Groeneveld AB. High volume hemofiltration improves hemodynamics and survival of pigs exposed to gut ischemia and reperfusion. Shock. 1994;2(1):72–8.

91. Laurent I, Adrie C, Vinsonneau C, Cariou A, Chiche JD, Ohanesian A, et al. High-volume hemofiltration after out-of-hospital cardiac arrest: a randomized study. J Am Coll Cardiol. 2005;46(3):432–7.

92. Shinozaki K, Lampe JW, Kim J, Yin T, Da T, Oda S, et al. The effects of early high-volume hemofiltration on prolonged cardiac arrest in rats with reperfusion by cardiopulmonary bypass: a randomized controlled animal study. Intensive Care Med Exp. 2016;4(1):25.

93. Geri G, Grimakdi D, Seguin T, Lamhaut L, Marin N, Chiche JD, et al. Hemodynamic efficiency of hemodialysis treatment with high cut-off membrane during the early period of post-resuscitation shock: The HYPERDIA trial. Resuscitation. 2019;140:170–7.

94. Tsai MS, Huang CH, Chang WT, Chen WJ, Hsu CY, Hsieh CC, et al. The effect of hydrocortisone on the outcome of out-of-hospital cardiac arrest patients: a pilot study. Am J Emerg Med. 2007;25(3):318–25.

95. Tsai MS, Chuang PY, Yu PH, Huang CH, Tang CH, Chang WT, et al. Glucocorticoid use during cardiopulmonary resuscitation may be beneficial for cardiac arrest. Int J Cardiol. 2016;222:629–35.

96. Mentzelopoulos SD, Malachias S, Chamos C, Konstantopoulos D, Ntaioud T, Papastylianou A, et al. Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial. JAMA. 2013;310(3):270–9.

97. Donnino MW, Andersen LW, Berg KM, Chase M, Sherwin R, Smithline H, et al. Corticosteroid therapy in refractory shock following cardiac arrest: a randomized, double-blind, placebo-controlled trial. Crit Care. 2016;20:82.

98. Tsai MS, Chuang PY, Huang CH, Tang CH, Yu PH, Chang WT, et al. Post-arrest steroid use may improve outcomes of cardiac arrest survivors. Crit Care Med. 2019;47(2):167–75.

99. Mayr V, Luckner G, Jochberger S, Wenzel V, Ulmer H, Pajk W, et al. Arginine vasopressin in advanced cardiovascular failure during the post-resuscitation phase after cardiac arrest. Resuscitation. 2007;72(1):35–44.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.